the breast: an overview lisa s. dresner, md, facs associate professor of surgery suny downstate
TRANSCRIPT
![Page 1: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/1.jpg)
The Breast: an Overview
Lisa S. Dresner, MD, FACS
Associate Professor of Surgery
SUNY Downstate
![Page 2: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/2.jpg)
Prevalence/Incidence
200,000 new cases in USA / year Incidence
– 121 / 100,000 white women– 99 / 100,000 black women
Stage– Increased numbers of early and non-invasive
cancers– Stable or slightly decreased number of advanced
Rates: vary geographically and ethnically Rates vary greatly by age
![Page 3: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/3.jpg)
![Page 4: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/4.jpg)
Current age
+10 yrs +20 yrs +30 yrs Eventually
0 0.00 0.00 0.05 13.22
10 0.00 0.05 0.48 13.37
20 0.05 0.48 1.92 13.40
30 0.44 1.88 4.49 13.41
40 1.46 4.11 7.56 13.14
50 2.73 6.30 9.64 12.06
60 3.82 7.40 9.52 9.99
Risk of Breast Cancer
Lifetime risk of dx: 13.22 %Lifetime risk of dying: 2.96 %
![Page 5: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/5.jpg)
![Page 6: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/6.jpg)
Anatomy
![Page 7: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/7.jpg)
Anatomy
![Page 8: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/8.jpg)
Structural Anatomy
![Page 9: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/9.jpg)
Physiology
Cell Regulation:– Growth development and function under hormone
control– Binding of hormone to specific cell receptors trigger
effects Estrogens:
– important in development, growth and differentiation. Normal and most malignant breast cells contain ER receptors.
– E-ER complex binds with nuclear chromatin and influences protein production including progesterone receptor (PR)
![Page 10: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/10.jpg)
History:
– Complaint, ask about SBE– Timing and nature of previous breast
surgery (atypia, cancer etc)– Family history of breast or ovarian cancer– Use of hormones– Reproductive history– Radiation exposure
![Page 11: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/11.jpg)
Physical Exam
Best/easiest during week after menses Palpate supraclavicular, cervical and axillary
nodes Skin changes: dimpling, edema, nipple
change With patient supine with hand over head
examine breast in a systematic way against the chest wall
![Page 12: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/12.jpg)
Evaluation of Breast Mass In women under 30 ultrasound In women over 30 mammo±ultrasound As a rule all except obviously benign masses should
have pathological diagnosis– Open biopsy– Core biopsy– FNA– Ultrasound guided core biopsy (highly sensitive and specific)
If the mass is indeterminate by your exam consider ultrasound to confirm
If mass not palpable stereotactic core biopsy
![Page 13: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/13.jpg)
Ultrasound guided biopsy
![Page 14: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/14.jpg)
Screening:
No controversy: all women aged 50 and older should have a mammogram every 1-2 years as well as an annual clinical breast exam (CBE)
Women 40-50: guidelines ACS mammogram every 1-2 years as well as an annual clinical breast exam (CBE)
High Risk: earlier mammography.
![Page 15: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/15.jpg)
![Page 16: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/16.jpg)
Mammogram: ACR Classification
Standardized way of reporting mammogram results.
BioRads Assessment
Category 0 Needs Additional Imaging Evaluation
Category 1 Negative (5/10,000 risk of breast cancer)
Category 2 Benign Finding (5/10,000 risk of breast cancer)
Category 3Probably Benign Finding: Short Interval Follow up Suggested (generally 6 months)
Category 4Suspicious Abnormality-Biopsy Should be considered (risk cancer 25-50%)
Category 5Highly suggestive of malignancy- Appropriate Action should be taken (obvious cancer: 75-100%risk)
![Page 17: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/17.jpg)
Circumscribed
Microlobulated
Obscured
Ill-defined
Spiculated
Masses:
Round
Oval
Lobulated
Irregular
![Page 18: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/18.jpg)
Infiltrating Carcinoma
![Page 19: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/19.jpg)
Microcalcifications: Concerning
![Page 20: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/20.jpg)
Microcalcs: Benign
![Page 21: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/21.jpg)
Cluster of irregular microcalcs.
![Page 22: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/22.jpg)
Management of Non-Palpable Mammographic abnormalities
Ultrasound: is there a mass?– Ultrasound guided core biopsy may be diagnostic
Stereotactic core biopsy– Mammographic abnormalities
Mammotome (mammo-guided very big core; may be excisional)
Needle localization biopsy– Mammo or ultrasound guided open biopsy
Cryoablation: for bx proven benign
![Page 23: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/23.jpg)
MRI for evaluation of the breast
Highly sensative but high false postive rate
Useful for screening BRCA patients May be useful in staging known breast
cancer May become an important screening
modality
![Page 24: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/24.jpg)
Stereotactic core biopsy
![Page 25: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/25.jpg)
Other imaging modalities
Tc99m sestamibi scan (Miraluma) Tomosynthesis (variation of
mammogram)
![Page 26: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/26.jpg)
MRI – Extremely sensitive (?high false positives?)
– May be useful in staging– May be useful in high risk patients with
difficult mammograms– Not yet approved for screening
![Page 27: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/27.jpg)
Benign Breast Disorders: 1
Fibrocystic “disease”– Nodular, lumpy, tender breasts:– Mastodynia– Clear/milky nipple discharge– Within the range of normal
Confirm benign-ness, Reassurance, symptomatic relief. Encourage BSE
Fibrocystic features– Adenosis, cysts, fibrosis (not increased risk)– Ductal and lobular hyperplasia with or without atypia
(with increased risk)
![Page 28: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/28.jpg)
Breast cysts:
A palpable mass could be a cyst– Simple cysts need no treatment
• Needle aspiration to confirm, or for pain relief• Ultrasound (conclusive)
– Complex cysts, bloody cysts deserve evaluation and biopsy (open or ultrasound guided core)
• Excision if diagnosis is in doubt after minimal invasive biopsy
![Page 29: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/29.jpg)
Breast cyst
![Page 30: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/30.jpg)
Fibroadenoma
May present at any age but most common women 16-24.
Rubbery, mobile, well defined Confirm by core, excision, FNA, or ultrasound,
and/or short interval observation by ultrasound Giant fibroadenomas: may be very large and
grow rapidly (late teens and perimenopause): RX: enucleation
Actual pathology may be adenoma, fibroadenoma,etc
![Page 31: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/31.jpg)
![Page 32: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/32.jpg)
Phylloides Tumor
Old name cystosarcoma phylloides Mesenchymal tumor: leaf like masses, cellular with
necrosis and hemorrhage May occur in adolescent (generally benign) or
premenopausal woman (may be malignant) Treated with excision with margins 25% risk of local recurrence in 10 years even with ‘benign”
path Mitotic figure count is one predictor of malignancy Metastasis even in “malignant” tumors are rare Younger: more likely benign, older women more likely
malignant
![Page 33: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/33.jpg)
Phylloides tumor:
![Page 34: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/34.jpg)
Other benign breast masses
Sclerosing adenosis Radial scar Fat necrosis Ductal ectasia Lactational mastitis and galactocele Mondor’s disease Intraductal papilloma Lactating adenoma
![Page 35: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/35.jpg)
Mastodynia
– Cyclical or continuous. May be referred to axilla, upper arm, may improve with menopause
– Rarely associated with malignancy– Continuous: may be related to a large
cyst,infection or inflammation– Reassurance, NSAIDS, well fitted brassiere,
caffeine reduction, evening primrose oil, cessation of tobacco use (takes months)
– Danazol, bromocriptine and tamoxifen (side effects prohibitive)
– ?SSRI
![Page 36: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/36.jpg)
Nipple Discharge
– Most common after lactation (as long as 2 years)– Subareolar infection (increased risk in smokers)– Galactorrhea (bilateral, milky) prolactin excess– Fibrocystic: green, yellow, brown (guiac)– Bloody: intraductal papilloma (benign), Cancer
should be ruled out. Ductogram (galactogram) may be helpful
![Page 37: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/37.jpg)
Hyperplasias: not malignant but not really benign either
Ductal hyperplasias– Mild– Moderate– Florid– Atypical Ductal hyperplasia (ADH)– (Ductal carcinoma in-situ- DCIS*)
Lobular hyperplasias– Lobular hyperplasia– Lobular carcinoma in-situ
![Page 38: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/38.jpg)
Lobular Carcinoma In-situ LCIS
Bystander lesion- marker of risk Commonly occurs in 4th decade of life, 2/3 are
premenopausal Lobular tumors are more likely ER/PR positive Diagnosis incidental on biopsy of other pathology Significant life time risk of breast cancer (5.9 to 12
times higher) but the risk is in both breasts Risk is greater 15-20 years after diagnosis than the
immediate post diagnostic period
![Page 39: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/39.jpg)
Lobular Carcinoma
Clinical features, epidemiology and risk factors and treatment not different
Doesn’t form microcalcifications and is extensively infiltrative so may be mammographically occult
May present as “architectural distortion on mamography
![Page 40: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/40.jpg)
Invasive Ductal Carcinoma
Most common tumor: from ductal elements Invasion of nerves, vessels, lymphatics in the
breast parenchyma at edge of lesions may be present and carries a poorer prognosis
May have all or partial characteristics of other types (colloid, tubular, medullary)
![Page 41: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/41.jpg)
Breast Cancer
![Page 42: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/42.jpg)
Breast Cancer Risk Factors
Greatly increased risk RR>4.0– Inherited genetic mutations for breast
cancer– ≥ 2 first degree relatives with breast cancer
diagnosed at early age– Personal history of breast cancer– Age >65 (increasing risk with increasing
age to 80)
![Page 43: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/43.jpg)
Breast Cancer Risk Factors
Moderately increased risk factors RR 2.1-4.0– One first degree relative with breast cancer– Nodular densities on mammogram (>75%
of volume)– Atypical hyperplasia on breast biopsy– High dose ionizing radiation to chest
![Page 44: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/44.jpg)
Breast Cancer Risk Factors 3
Low increased risk: RR 1.1-2High socioeconomic status, urban residence, Northern USA
Early menarche (<12), late menopause (>55)
No full term pregnancy, late (>30) first term pregnancy
Never breast fed
Postmenopausal obesity
Etoh,consumption
HRT, recent oca use
Tall
Personal history of ca endometrium, ovary or colon
Jewish heritage, mammographically dense breasts
![Page 45: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/45.jpg)
Inherited Breast Cancer Syndromes 1. Li-Fraumeni syndrome: p53 mutation 2. Mutation on the sht arm of chromosome 2 3. BRCA-1 long arm chromosome 17 (associated
with breast and ovarian cancer) 4. BRCA-2 small region of 13q12-13 Recommendations vary from bilateral salpingo-
oophorectomy and prophylactic mastectomy to increased surveillance
Value of SERM (tamoxifen) unclear as most hereditary-linked breast cancers are ER/PR negative
![Page 46: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/46.jpg)
Estimating Risk Gail Model
– calculates risk using 6 key risk factors• Age• Age menarche• Age first birth• Family history (1° female relative)• Number of previous breast biopsies• Number of biopsies with atypical hyperplasia
http://bcra.nci.nih.gov/brc/
![Page 47: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/47.jpg)
Inflammatory breast cancer
Diagnosis: clinical findings of inflamed breast with underlying malignancy.
35% have obvious mets at time of diagnosis Mammogram: edema Dermal or core biopsy Treatment is neoadjuvant chemotherapy first
then mastectomy plus RT
![Page 48: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/48.jpg)
Inflammatory Breast Cancer
![Page 49: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/49.jpg)
Inflammatory Breast Cancer
![Page 50: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/50.jpg)
Staging
Primary tumor– Tis: Carcinoma in-situ– T1 : 2 cm or less– T2 : >2 but not more than 5 cm– T3 : >5 cm– T4 : any size with chest wall extension,
skin involvement, skin nodules, or inflammatory breast cancer
![Page 51: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/51.jpg)
Staging
Nodes– N0 no involved nodes– N1 mets to ipsilateral nodes (movable)– N2 mets to ipsilateral nodes matted/fixed– N3 ipsilateral internal mammary nodes
Metastasis– M0, M1
![Page 52: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/52.jpg)
Stage Groups
Stage 0 Tis, N0, M0 Stage 1 T1, N0, M0 Stage IIA T0-1, N1,M0 T2 , N0, M0 Stage IIB T2, N1, M0 T3, N0, M0 Stage IIIA T0-2, N2, M0 T3, N1-2, M0 Stage IIIB T4, N1-2, M0 Any T, N3, M0 Stage IV Any T, Any N, M1
![Page 53: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/53.jpg)
Tumor related prognostic factors
Size ER and PR status Margins Histologic type Pathologic prognostic features
– Nuclear grade, angiolymphatic invasion, lymphocytic response
Invasivion: DCIS vs infiltrating intraductal I– invasion of basement membrane– Often both on same specimen
![Page 54: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/54.jpg)
Breast Cancer:Treatment Options
Local control:– Lumpectomy with irradiation– Mastectomy ± reconstruction
Regional Control– Axillary lymph node dissection– Regional RT
![Page 55: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/55.jpg)
Neoadjuvant Chemotherapy
Recommended for Stage IV, and some III and IIb patients
May allow breast conservation therapy in women by downstaging tumor.
Unclear yet that it improves survival but good response is a good prognostic sign
![Page 56: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/56.jpg)
Sentinal node biopsy
New standard for clinically negative axilla Avoids full axillary dissection and its
complications in patients with small tumors and negative node status
blue dye plus nuclear medicine Axillary node evaluation done to identify
node positive patients so as to guide adjuvant therapy
“Proven” benefit in women with T1 tumors (where axillary node infrequently involved)
![Page 57: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/57.jpg)
Breast Conservation
Quality of results improved by increasing facility with autologous flaps and use of tissue expanders
Improved quality of result with advent of skin sparing mastectomy
Options include flaps (Tram, latissimus), free flaps, and implants.
![Page 58: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/58.jpg)
Skin sparing mastectomy
![Page 59: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/59.jpg)
Adjuvant therapy
Chemotherapy– Decreases rate of distant recurrence– Recommended for stage stage II breast cancers
Hormonal therapy– Effect in ER/PR positive breast cancers similar to
chemotherapy– New agents (aromatase inhibitors) may supplant
Tamoxifen in the next few years in post menopausal patients
![Page 60: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/60.jpg)
Recommendations for Adjuvant therapy in stage I and II Breast CancerPremenopausal Postmenopausal
Tumor ER positive ER-Negative ER positive ER-Negative
<1 cm, negativenodes
ø ø ø ø
≥ 1 cm, negativenodes
Tam ± chemo Chemo Tam Chemo
Positive Nodes Chemo Chemo Tam Chemo
Adjuvant Therapy
![Page 61: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/61.jpg)
On the horizon
Ductal Lavage and FNA Digital mammography Bone marrow biopsy
and staging Sentinal node biopsy ? Axillary node dissection? Aromatase therapy will supplant Tamoxifen Increasing number of women with low stage
tumors receiving chemotherapy Life long treatment with aromatase inhibitors
![Page 62: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/62.jpg)
Prevention: Bilateral mastectomy
– Bilateral mastectomy decreases the risk of breast cancer by 90%
Salpingo-oophorectomy– Recent study demonstrated significant decrease in new
breast cancer risk in BRCA carrier women Chemoprevention
– Tamoxifen– ?Raloxifen: trials ongoing– ?Aromatase inhibitors?– Chemoprevention is less likely to be effective in BRCA1
tumors (greater # receptor negative tumors)
![Page 63: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/63.jpg)
![Page 64: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/64.jpg)
Internet resources:
Susan B Komen Foundation:http://www.komen.org/
National Cancer Institutehttp://www.nci.nih.gov/cancertopics/
types/breast
![Page 65: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/65.jpg)
Mechanism of Action of Aromatase Inhibitors and Tamoxifen
![Page 66: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/66.jpg)
Aromatase Inhibitors
Lower circulating estrogens by preventing peripheral production of estrogens
anastrazole = Arimidex letrozole = Femara exemestane = Aromasin Each has been studies in different
clinical circumstances
![Page 67: The Breast: an Overview Lisa S. Dresner, MD, FACS Associate Professor of Surgery SUNY Downstate](https://reader036.vdocuments.net/reader036/viewer/2022062422/56649ddf5503460f94ad80eb/html5/thumbnails/67.jpg)